Hair Loss News and Research

RSS

IQWiG study finds no added benefit of teriflunomide

Teriflunomide (trade name: Aubagio) has been approved in Germany since August 2013 for adults with relapsing remitting multiple sclerosis. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the appropriate comparator therapy specified by the Federal Joint Committee (G-BA).

8 Jan 2014

Endocrine Society issues scientific statement on health consequences of performance-enhancing drugs

A new Scientific Statement issued today by The Endocrine Society represents a comprehensive evaluation of available information on the prevalence and medical consequences of the use of performance-enhancing drugs. The statement highlights the clinical pharmacology, adverse effects and detection of many substances often classified as PEDs, identifies gaps in knowledge and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem.

18 Dec 2013

Methodology needed to diagnose quality of life of individual cancer patients or survivors

Due to improved treatments and technologies, more children than ever are surviving cancer. Unfortunately, about 70 percent of these children experience late effects from their disease and treatment 30 years after their cancer diagnosis, which University of Florida Health researchers say significantly impact their quality of life.

13 Dec 2013

Manipulation of Wnt/B-catenin pathway provides therapeutic targets for hair loss, skin cancer

A pathway known for its role in regulating adult stem cells has been shown to be important for hair follicle proliferation, but contrary to previous studies, is not required within hair follicle stem cells for their survival, according to researchers with the Perelman School of Medicine at the University of Pennsylvania.

5 Dec 2013

Researchers identify new mechanism that causes neurodegeneration

As we age, our body rhythms lose time before they finally stop. Breaking the body clock by genetically disrupting a core clock gene, Bmal1, in mice has long been known to accelerate aging , causing arthritis, hair loss, cataracts, and premature death.

26 Nov 2013

Dermatologist offers tips for healthy hair when using hair treatments

While coloring your hair is a common beauty treatment, the process can leave your hair dry and brittle. Fortunately, dermatologists, who are experts in the care of the skin, hair and nails, offer tips for coloring and perming your hair while keeping it healthy.

13 Nov 2013

Lupus disparities: Young, black women have highest rate of developing lupus

Young, black women have the highest rate of developing lupus and are most likely to be diagnosed at a younger age than whites and during childbearing years, according to a new University of Michigan study of lupus in Southeastern Michigan.

25 Oct 2013

CUMC develops new technique that uses patient's own cells to grow new hair

Researchers at Columbia University Medical Center (CUMC) have devised a hair restoration method that can generate new human hair growth, rather than simply redistribute hair from one part of the scalp to another.

22 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

FDA grants accelerated approval to Perjeta for neoadjuvant treatment of breast cancer

The U.S. Food and Drug Administration today granted accelerated approval to Perjeta (pertuzumab) as part of a complete treatment regimen for patients with early stage breast cancer before surgery (neoadjuvant setting). Perjeta is the first FDA-approved drug for the neoadjuvant treatment of breast cancer.

1 Oct 2013

Messages that warn consumers about potentially harmful side effects increase product sales

Drug ads often warn of serious side effects, from nausea and bleeding to blindness, even death. New research suggests that, rather than scaring consumers away, these warnings can improve consumers' opinions and increase product sales when there is a delay between seeing the ad and deciding to buy or consume the product.

24 Sep 2013

New study to reduce unwanted side-effects of radiotherapy

Scientists from The University of Manchester are leading a new European study to come up with methods to reduce the unwanted side-effects of radiotherapy and improve cancer treatment.

From The University of Manchester 12 Sep 2013

Novel viral therapy to treat specific types of cancer in children

Parents do everything they can to protect their children against all of the nasty germs floating around classrooms across the country this time of year. Doctors and researchers at Nationwide Children's Hospital, however, are looking into how those same types of common viruses can actually help treat a child who is diagnosed with certain cancers.

10 Sep 2013

FDA approves use of abraxane to treat patients with late-stage pancreatic cancer

The U.S. Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

7 Sep 2013

Greenwich Hospital's new radiation oncology therapy gives renewed hope to HRPC patients

At the end of July, Greenwich became the only hospital in New York City, Westchester and Fairfield counties to offer Xofigo, commonly referred to as Radium 223, a new radiation oncology therapy that is giving renewed hope to patients with stage 4 hormone-refractory prostate cancer.

6 Sep 2013

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel Pharmaceuticals, Inc. today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura pending discussions with regulatory agencies.

5 Sep 2013

Managing insulin levels through meal timing boosts ovulation in women with PCOS

Polycystic Ovarian Syndrome (PCOS), a common disorder that impairs fertility by impacting menstruation, ovulation, hormones, and more, is closely related to insulin levels. Women with the disorder are typically "insulin resistant" - their bodies produce an overabundance of insulin to deliver glucose from the blood into the muscles.

14 Aug 2013

One step closer to understanding how to control cancer cells without harming healthy ones

The nasty side effects of radiation and chemotherapy are well known: fatigue, hair loss and nausea, to name a few. Cancer treatment can seem as harsh as the disease because it can't differentiate healthy cells from cancerous cells, killing both.

17 Jul 2013

Antibodies boost immune system to fight childhood cancer, shows study

Researchers in the Antibody and Vaccine Group have developed two monoclonal antibodies (mAbs) called anti-4-1BB and anti-CD40 and investigated a third called anti-CTLA-4. Each of these antibodies binds to a different target molecule in the immune system, potentially heightening the body's own immune response to cancer.

12 Jul 2013

Dr. Mirmirani shares tips for preventing hair damage and hair loss

How you style your hair, along with the styling tools you use, can cause significant hair damage. This damage can cause your hair to look brittle, frizzy and lackluster or even fall out. The good news is that you can prevent damage by following tips from dermatologists.

10 Jul 2013